Scott Farley
Birmingham, ALNPI 1487274429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $2,093, more than ten times the $29 reported in 2023.
Across 118 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$860
- Johnson & Johnson$579
- Takeda Pharmaceuticals U.S.A., Inc.$252
- Sanofi$242
- Madrigal Pharmaceuticals$168
- Regeneron Healthcare Solutions, Inc.$167
- plus $864 from 16 others
What the payments were for
- Food & beverage$3,132100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $860 |
| Johnson & Johnson | 20 | $579 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $252 |
| Sanofi | 5 | $242 |
| Madrigal Pharmaceuticals | 8 | $168 |
| Regeneron Healthcare Solutions, Inc. | 5 | $167 |
| Ardelyx, Inc. | 6 | $126 |
| Olympus America Inc. | 1 | $120 |
| Janssen Scientific Affairs, LLC | 1 | $97 |
| Aimmune Therapeutics, Inc. | 5 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Gilead | 3 | $61 |
| Lilly USA, LLC | 3 | $59 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Medtronic | 1 | $47 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Boston Scientific | 1 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $19 |
| Pfizer | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LoperamideLoperamide Hcl | 27 | $739 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $212 |
| Omeprazole | 11 | $118 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.